A new trading day began on Monday, with Verona Pharma Plc ADR (NASDAQ: VRNA) stock price down -5.10% from the previous day of trading, before settling in for the closing price of $64.65. VRNA’s price has ranged from $11.39 to $70.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -39.77% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 128.70%. With a float of $74.21 million, this company’s outstanding shares have now reached $84.63 million.
In an organization with 209 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 92.63%, operating margin of -365.87%, and the pretax margin is -389.38%.
Verona Pharma Plc ADR (VRNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 12.31%, while institutional ownership is 69.61%. The most recent insider transaction that took place on Dec 05 ’24, was worth 3,205,226. In this transaction President and CEO of this company sold 640,264 shares at a rate of $5.01, taking the stock ownership to the 14,367,552 shares. Before that another transaction happened on Dec 06 ’24, when Company’s President and CEO sold 162,800 for $5.01, making the entire transaction worth $815,400. This insider now owns 14,204,752 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 128.70% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Here are Verona Pharma Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 123.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.16, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.51 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.32 million. That was inferior than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.62%. Additionally, its Average True Range was 3.61.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 76.68%, which indicates a significant increase from 16.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.06% in the past 14 days, which was higher than the 51.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.92, while its 200-day Moving Average is $34.79. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $64.13. Second resistance stands at $66.90. The third major resistance level sits at $69.22. If the price goes on to break the first support level at $59.04, it is likely to go to the next support level at $56.72. Assuming the price breaks the second support level, the third support level stands at $53.95.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
With a market capitalization of 5.19 billion, the company has a total of 80,820K Shares Outstanding. Currently, annual sales are 42,280 K while annual income is -173,420 K. The company’s previous quarter sales were 36,660 K while its latest quarter income was -33,830 K.
